Gossamer Bio (GOSS) Receives a Buy From Piper Sandler
Gossamer Bio Analyst Ratings
Gossamer Bio Analyst Ratings
Buy Rating Reaffirmed for Gossamer Bio on Seralutinib's Promising Clinical Data and Future Prospects
Gossamer Bio Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Gossamer Bio, Maintains $10 Price Target
Buy Rating Affirmed for Gossamer Bio Amidst Strategic Collaboration and Market Opportunity Growth
Gossamer Bio Analyst Ratings
Wedbush Reiterates Outperform on Gossamer Bio, Maintains $4 Price Target
Strategic Partnership and Financial Upside: Gossamer Bio Earns a Buy Rating
Analysts Offer Insights on Healthcare Companies: Gossamer Bio (GOSS), RxSight (RXST) and Edwards Lifesciences (EW)
Buy Rating on Gossamer Bio Supported by Strategic Partnership and Market Underestimation
Gossamer Bio Analyst Ratings
Analysts Have Conflicting Sentiments on These Healthcare Companies: GlycoMimetics (GLYC) and Gossamer Bio (GOSS)
Gossamer Bio Analyst Ratings
Gossamer Bio Analyst Ratings
Buy Rating Affirmed on Gossamer Bio With Promising Seralutinib Prospects in PAH Treatment Landscape
Gossamer Bio (GOSS) Receives a Buy From Piper Sandler
Analysts Offer Insights on Healthcare Companies: Diamedica Therapeutics (DMAC), Gossamer Bio (GOSS) and Vor Biopharma (VOR)
Piper Sandler Sticks to Its Buy Rating for Gossamer Bio (GOSS)